-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
DAPA-HF is the first study to apply SGLT2 inhibitors to heart failure outcomes in patients with reduced blood-semia scores (HFrEF) with or withor type 2 diabetesDagrenet is currently approved for the treatment of people with type 2 diabetesthe topline results released in August 2019 show eddy DAPA-HF has reached its main destinationDetailed results of the DAPA-HF study presented today at the ESC conference in Paris, France, showed that the net ability of Dagrell significantly reduced the risk of major compound endpoints of cardiovascular (CV) death or deterioration of heart failure by 26% (p0.0001) and significantly reduced in all components of the main compound endpointDAPA-HF study also separately analyzed the components of the main composite endpointsThe risk of first deterioration of heart failure in the Dugley net group decreased by 30% (p 0.0001) and the risk of death due to cardiovascular disease decreased by 18% (p-0.0294)The net effect of Daglenet on the main composite endpoint was generally consistent in the key subgroups in the studyresults also showed a significant improvement in the overall symptom score of the Dagrenet Net Group in the Kansas City Cardiopathy Patient Quality Of Life Scale (KCCQ) submitted by patientsAt the same time, the risk of all-cause dying was significantly reduced by 17% (7.9 vs 9.5 incidents per 100 patients-year)the safety status of the DAPA-HF study was consistent with the safety of the drug's previously confirmed safetyThe incidence of low blood volume (7.5% vs 6.8%) and renal adverse events (6.5% vs 7.2%) was comparable to placeboIn both treatment groups, severe hypoglycemia events (0.2% vs 0.2%)were rarein addition, the DELIVER study and THE METHOD OF THE FINAL (HFrEF and HFpEF) studies in patients with blood-saggling scores are also under wayAt present, Dagrenet has not been approved in China to improve cardiovascular risk or kidney risk related indications, and has not been approved for use in non-type 2 diabetes patientsReferences:1, Mayo ClinicHeart failure; 2017 (cited 2019 Aug 14) Available from URL: https:// 2, and national Vos, prevalence, and years lived mewn for 328 diseases and senses for 195 countries, 1990-2016: A-innings analysis for the Global Burden of Disease Study 2016 The Lancet 2017; 390(10100):1211–59 3, Mozaffarian D et al Circulation 2016 Jan 26; 133 (4): e38-360 and the CDC: https:// 4, Bhuiyan, Taslima, and Mathew Sur Maurer "Heart Fraction with Preserved Ejection: Persistent Diagnosis, Therapeutic Enigma." Current cardiovascular risk reports vol.
5,5 (2011): 440-449 doi: 10.1007/s12170-011-0184-25, Mamas, M A., Sperrin, M., Watson, M.C., Coutts, A., Wilde, K., Burton, C., Myint, P K (2017) Do patients have sworse outcomes in heart down than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland European Journal of Heart Failure, 19 (9), 1095-1104 https://doi.org/10.1002/ejhf.822 6, Azad, N., and Lemay, G (2014) Management of heart chronic ness in the older population Journal of Geriatric Cardiology: JGC, 11 (4), 329-37.